Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers raised its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 1.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 132,873 shares of the company’s stock after purchasing an additional 1,912 shares during the period. Rhumbline Advisers owned 0.11% of Apellis Pharmaceuticals worth $12,105,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cim Investment Management Inc. boosted its stake in Apellis Pharmaceuticals by 3.6% during the 1st quarter. Cim Investment Management Inc. now owns 4,744 shares of the company’s stock valued at $313,000 after purchasing an additional 163 shares during the period. Advisor Group Holdings Inc. boosted its stake in Apellis Pharmaceuticals by 6.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,249 shares of the company’s stock valued at $167,000 after purchasing an additional 209 shares during the period. Neuberger Berman Group LLC lifted its holdings in Apellis Pharmaceuticals by 0.7% in the third quarter. Neuberger Berman Group LLC now owns 44,334 shares of the company’s stock worth $3,028,000 after purchasing an additional 290 shares during the period. National Bank of Canada FI acquired a new stake in Apellis Pharmaceuticals in the second quarter worth about $33,000. Finally, Clearstead Advisors LLC acquired a new stake in Apellis Pharmaceuticals in the first quarter worth about $27,000. 90.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 9th. They issued a “buy” rating and a $74.00 price objective for the company. Raymond James upped their price objective on shares of Apellis Pharmaceuticals from $92.00 to $93.00 and gave the stock a “strong-buy” rating in a report on Thursday, November 2nd. UBS Group upped their price objective on Apellis Pharmaceuticals from $60.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, August 23rd. Bank of America upped their price objective on Apellis Pharmaceuticals from $44.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, October 12th. Finally, Citigroup upped their price objective on Apellis Pharmaceuticals from $54.00 to $70.00 and gave the company a “buy” rating in a report on Friday, October 6th. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $66.50.

Apellis Pharmaceuticals Trading Up 0.8 %

Apellis Pharmaceuticals stock opened at $49.50 on Tuesday. Apellis Pharmaceuticals, Inc. has a 52 week low of $19.83 and a 52 week high of $94.75. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.76 and a current ratio of 4.29. The firm has a market capitalization of $5.87 billion, a price-to-earnings ratio of -9.43 and a beta of 0.97. The company has a 50 day moving average price of $45.13 and a 200 day moving average price of $57.95.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Wednesday, November 1st. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.29). The business had revenue of $110.40 million during the quarter, compared to analysts’ expectations of $99.05 million. Apellis Pharmaceuticals had a negative net margin of 222.16% and a negative return on equity of 209.10%. Apellis Pharmaceuticals’s revenue for the quarter was up 400.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.75) EPS. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -4.59 EPS for the current year.

Insider Activity

In other news, Director Alec Machiels sold 1,250 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $47.74, for a total value of $59,675.00. Following the completion of the sale, the director now owns 367,420 shares in the company, valued at $17,540,630.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Apellis Pharmaceuticals news, Director Alec Machiels sold 1,250 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $47.74, for a total value of $59,675.00. Following the completion of the sale, the director now owns 367,420 shares in the company, valued at approximately $17,540,630.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Pascal Deschatelets sold 12,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $42.87, for a total transaction of $514,440.00. Following the completion of the sale, the insider now owns 1,059,813 shares of the company’s stock, valued at approximately $45,434,183.31. The disclosure for this sale can be found here. Insiders sold 212,164 shares of company stock worth $8,997,686 over the last quarter. Corporate insiders own 7.50% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).